Daxor (DXR) director granted 2,500 stock options at $10.14

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Daxor Corp director Joy S. Goudie reported receiving a grant of 2,500 stock options to buy common stock at an exercise price of $10.14 per share. The options expire on June 23, 2031 and are scheduled to vest in three annual installments from June 23, 2026 through June 23, 2028. The grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Goudie Joy S.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	2,500	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 2,500 shares (Direct, null)

Footnotes (1)

Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)

Key Figures

Options granted: 2,500 options Exercise price: $10.14 per share Expiration date: June 23, 2031 +4 more

7 metrics

Options granted 2,500 options Stock options granted to director on June 23, 2026

Exercise price $10.14 per share Exercise price for Daxor common stock under the options

Expiration date June 23, 2031 Option expiration for the 2,500 granted options

Vesting 2026 833 options First vesting installment on June 23, 2026

Vesting 2027 883 options Second vesting installment on June 23, 2027

Vesting 2028 834 options Third vesting installment on June 23, 2028

Post-grant derivative holdings 2,500 options Total stock options held following this transaction

Key Terms

Stock Options (right to buy), exercise price, expiration date, 2020 Incentive Compensation Plan, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

exercise price financial

"conversion_or_exercise_price: 10.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2031-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

2020 Incentive Compensation Plan financial

"to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan")"

vest financial

"The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 05:16 PM Accepted by SEC EDGAR 06/25/2026 - 05:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goudie Joy S.

(Last)

(First)

(Middle)

109 MECO LANE

(Street)

OAK RIDGE,

TENNESSEE

37830

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (right to buy)	$10.14	06/23/2026⁽¹⁾		A		2,500		⁽²⁾	06/23/2031	COMMON STOCK	2,500	$0	2,500	D

Explanation of Responses:

1. Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").

2. The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)

	/s/ Joy Goudie	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DAXOR (DXR) director Joy S. Goudie report?

Joy S. Goudie reported receiving 2,500 stock options as a compensation grant. These options give her the right to buy Daxor common stock at a fixed exercise price and are subject to vesting and plan approval conditions.

What are the key terms of Joy S. Goudie’s DAXOR (DXR) stock options?

The grant covers 2,500 stock options with a $10.14 per share exercise price. The options expire on June 23, 2031 and relate to Daxor’s common stock under the company’s 2020 Incentive Compensation Plan.

How and when do Joy S. Goudie’s DAXOR (DXR) options vest?

The options vest in three tranches: 833 options on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028. Vesting spreads the economic benefit over three years, aligning with longer-term service.

Are Joy S. Goudie’s DAXOR (DXR) option grants subject to any approvals?

Yes. The stock options are contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. This means the grant depends on regulatory clearance of the updated plan terms.

How many DAXOR (DXR) derivative securities does Joy S. Goudie hold after this Form 4?

After this transaction, Goudie holds 2,500 stock options directly according to the filing. This reflects her total reported derivative position related to these options following the grant on June 23, 2026.